Overview

            Xalud Therapeutics, Inc. is developing novel therapies for the treatment of neuro-inflammatory diseases including neuropathic pain, multiple sclerosis and ALS. Xalud's lead product, XT-101, has shown exceptional efficacy in leading models of both neuropathic and chronic pain as well in the EAE model of multiple sclerosis.

        Xalud (pronounced as "Salud", to your health!) is currently conducting IND-enabling toxicology and related studies and expects to file an IND in 2013 for a neuropathic pain indication. At the same time, the Company is continuing its research into the applicability of XT-101 for MS and ALS.

         Based in the San Francisco Bay Area, Xalud has received significant support from the NIH and private investors

Xalud will be presenting at the Biotech Showcase in San Francisco on January 9th.